Cargando…
Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis
BACKGROUND: The COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systema...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822543/ https://www.ncbi.nlm.nih.gov/pubmed/35131810 http://dx.doi.org/10.1136/bmjopen-2020-044661 |
_version_ | 1784646623814483968 |
---|---|
author | Han, Shuting Zhuang, Qingyuan Chiang, Jianbang Tan, Sze Huey Chua, Gail Wan Ying Xie, Conghua Chua, Melvin L K Soon, Yu Yang Yang, Valerie Shiwen |
author_facet | Han, Shuting Zhuang, Qingyuan Chiang, Jianbang Tan, Sze Huey Chua, Gail Wan Ying Xie, Conghua Chua, Melvin L K Soon, Yu Yang Yang, Valerie Shiwen |
author_sort | Han, Shuting |
collection | PubMed |
description | BACKGROUND: The COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systematic review and meta-analysis (MA). METHODS: Systematic review was performed through online databases, PubMed, Medline and Google Scholar, with keywords listed in the Methods section (1 November 2019–31 December 2020). Studies with clinical outcomes of at least 10 COVID-19 patients and at least one with a diagnosis of cancer were included. The studies for MA were assessed with PRISMA guidelines and appraised with Newcastle-Ottawa Scale. The data were pooled using a random-effects model using STATA software. The main outcomes were planned before data collection, including proportion of patients with cancer among COVID-19 populations, relative risk (RR) of severe outcomes and death of patients with cancer compared with general COVID-19 patients. RESULTS: We identified 57 case series (63 413 patients), with 230 patients with cancer with individual patient data (IPD). We found that the pooled proportion of cancer among COVID-19 patients was 0.04 (95% CI 0.03 to 0.05, I(2)=97.69%, p<0.001). The pooled RR of death was 1.44 (95% CI 1.19 to 1.76) between patients with cancer and the general population with COVID-19 infection. The pooled RR of severe outcome was 1.49 (95% CI 1.18 to 1.87) between cancer and general COVID-19 patients. The presence of lung cancer and stage IV cancer did not result in significantly increased RR of severe outcome. Among the available IPD, only age and gender were associated with severe outcomes. CONCLUSION: Patients with cancer were at a higher risk of severe and death outcomes from COVID-19 infection as compared with general COVID-19 populations. Limitations of this study include publication bias. A collaborative effort is required for a more complete database. |
format | Online Article Text |
id | pubmed-8822543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-88225432022-02-09 Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis Han, Shuting Zhuang, Qingyuan Chiang, Jianbang Tan, Sze Huey Chua, Gail Wan Ying Xie, Conghua Chua, Melvin L K Soon, Yu Yang Yang, Valerie Shiwen BMJ Open Oncology BACKGROUND: The COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systematic review and meta-analysis (MA). METHODS: Systematic review was performed through online databases, PubMed, Medline and Google Scholar, with keywords listed in the Methods section (1 November 2019–31 December 2020). Studies with clinical outcomes of at least 10 COVID-19 patients and at least one with a diagnosis of cancer were included. The studies for MA were assessed with PRISMA guidelines and appraised with Newcastle-Ottawa Scale. The data were pooled using a random-effects model using STATA software. The main outcomes were planned before data collection, including proportion of patients with cancer among COVID-19 populations, relative risk (RR) of severe outcomes and death of patients with cancer compared with general COVID-19 patients. RESULTS: We identified 57 case series (63 413 patients), with 230 patients with cancer with individual patient data (IPD). We found that the pooled proportion of cancer among COVID-19 patients was 0.04 (95% CI 0.03 to 0.05, I(2)=97.69%, p<0.001). The pooled RR of death was 1.44 (95% CI 1.19 to 1.76) between patients with cancer and the general population with COVID-19 infection. The pooled RR of severe outcome was 1.49 (95% CI 1.18 to 1.87) between cancer and general COVID-19 patients. The presence of lung cancer and stage IV cancer did not result in significantly increased RR of severe outcome. Among the available IPD, only age and gender were associated with severe outcomes. CONCLUSION: Patients with cancer were at a higher risk of severe and death outcomes from COVID-19 infection as compared with general COVID-19 populations. Limitations of this study include publication bias. A collaborative effort is required for a more complete database. BMJ Publishing Group 2022-02-07 /pmc/articles/PMC8822543/ /pubmed/35131810 http://dx.doi.org/10.1136/bmjopen-2020-044661 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Oncology Han, Shuting Zhuang, Qingyuan Chiang, Jianbang Tan, Sze Huey Chua, Gail Wan Ying Xie, Conghua Chua, Melvin L K Soon, Yu Yang Yang, Valerie Shiwen Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis |
title | Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis |
title_full | Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis |
title_fullStr | Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis |
title_full_unstemmed | Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis |
title_short | Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis |
title_sort | impact of cancer diagnoses on the outcomes of patients with covid-19: a systematic review and meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822543/ https://www.ncbi.nlm.nih.gov/pubmed/35131810 http://dx.doi.org/10.1136/bmjopen-2020-044661 |
work_keys_str_mv | AT hanshuting impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT zhuangqingyuan impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT chiangjianbang impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT tanszehuey impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT chuagailwanying impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT xieconghua impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT chuamelvinlk impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT soonyuyang impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis AT yangvalerieshiwen impactofcancerdiagnosesontheoutcomesofpatientswithcovid19asystematicreviewandmetaanalysis |